)
Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company, has received two product patents from Israel, and a patent each from Japan, China and New Zealand corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.
These patents are valid through 2027, 2028, 2029 and 2030 respectively.
In a filing to the BSE on Friday, Suven Life said the patent includes the class of selective 5-HT compounds discovered by Suven.
These were being developed as therapeutic agents to be used in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's, attention deficiency hyperactivity disorder (ADHD), Huntington's, Parkinson and schizophrenia diseases.
With these new patents, Suven has two granted patents from Israel, 11 from Japan, 15 from China and 21 from New Zealand.
Products out of these innovations may be out-licensed at various phases of clinical development like at Phase-I and Phase-II, the company said.
Suven Life's scrip is currently trading at Rs 222 on the BSE, up 5.74%, over the previous close of Rs 209.95 a share.
